PT  - JOURNAL ARTICLE
AU  - Lassen, Frederik H.
AU  - Venkatesh, Samvida S.
AU  - Baya, Nikolas
AU  - Zhou, Wei
AU  - Bloemendal, Alex
AU  - Neale, Benjamin M.
AU  - Kessler, Benedikt M.
AU  - Whiffin, Nicola
AU  - Lindgren, Cecilia M.
AU  - Palmer, Duncan S.
TI  - Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank
AID  - 10.1101/2023.06.29.23291992
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.29.23291992
4099  - http://medrxiv.org/content/early/2023/07/03/2023.06.29.23291992.short
4100  - http://medrxiv.org/content/early/2023/07/03/2023.06.29.23291992.full
AB  - Exome-sequencing association studies have successfully linked rare protein-coding variation to risk of thousands of diseases. However, the relationship between rare deleterious compound heterozygous (CH) variation and their phenotypic impact has not been fully investigated. Here, we leverage advances in statistical phasing to accurately phase rare variants (MAF ∼ 0.001%) in exome sequencing data from 175,587 UK Biobank (UKBB) participants, which we then systematically annotate to identify putatively deleterious CH coding variation. We show that 6.5% of individuals carry such damaging variants in the CH state, with 90% of variants occurring at MAF < 0.34%. Using a logistic mixed model framework, systematically accounting for relatedness, polygenic risk, nearby common variants, and rare variant burden, we investigate recessive effects in common complex diseases. We find six exome-wide significant (𝑃 < 1.68 × 10−7) and 17 nominally significant (𝑃 < 5.25 × 10−5) gene-trait associations. Among these, only four would have been identified without accounting for CH variation in the gene. We further incorporate age-at-diagnosis information from primary care electronic health records, to show that genetic phase influences lifetime risk of disease across 20 gene-trait combinations (FDR < 5%). Using a permutation approach, we find evidence for genetic phase contributing to disease susceptibility for a collection of gene-trait pairs, including FLG-asthma (𝑃 = 0.00205) and USH2A-visual impairment (𝑃 = 0.0084). Taken together, we demonstrate the utility of phasing large-scale genetic sequencing cohorts for robust identification of the phenome-wide consequences of compound heterozygosity.Competing Interest StatementB.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora. All other authors declare no competing interests.Funding StatementF.H.L. is supported by the Wellcome Trust (award 224894/Z/21/Z), and the Medical Sciences Doctoral Training Centre at the University of Oxford. S.S.V. is supported by the Rhodes Scholarship, Clarendon Fund, and the Medical Sciences Doctoral Training Centre at the University of Oxford. N.B. is supported by the Clarendon Fund, and the Medical Sciences Doctoral Training Centre at the University of Oxford. W.Z. is supported by the National Human Genome Research Institute of the National Institutes of Health under award number K99HG012222. A.B. is supported by the Novo Nordisk Center for Genomic Mechanisms of Disease at the Broad Institute (NNF21SA0072102). N.W. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (220134/Z/20/Z) and research grant funding from the Rosetrees Trust (PGL19-2/10025). C.M.L. is supported by the Li Ka Shing Foundation, NIHR Oxford Biomedical Research Centre, Oxford, NIH (1P50HD104224-01), Gates Foundation (INV-024200), and a Wellcome Trust Investigator Award (221782/Z/20/Z). This research has been conducted using the UK Biobank resource under application Number 10844.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used data from the UK Biobank. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe code required to reproduce our analyses is publicly available at https://github.com/frhl/wes_ko_ukbb. Data produced in the present study are available upon reasonable request to the authors.